TUSTIN, CA--(Marketwire - March 08, 2011) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) responded today as its stock has been halted by the New York Stock Exchange (NYSE) due to unusual trading activity believed to be caused by an inaccurate article published on ‘TheStreet.com’ on March 7, 2011 regarding RPC’s collaboration with a nonprofit worldwide leader in medical care, research and education and its study to compare the effectiveness of RPC’s Onko-Sure® In Vitro diagnostic (IVD) cancer test to the Carcino-Embryonic Antigen (CEA) marker in a large population of patients (N=976) with all stages of colorectal cancer.
RPC is taking proactive steps to address the article and intends to issue a public statement later today providing existing and prospective shareholders with information correcting certain inaccuracies set forth in the article. For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or send e-mail to info@radient-pharma.com. For Investor Relations contact Kristine Szarkowitz at IR@RadientPharma.com or 1.206.310.5323.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
RPC Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
(Tel : ) 206.310.5323
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
